Université De Montréal is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Location: Montreal, Quebec, Canada
Type: Public Research University
Founded: 1878
Website: [umontreal.ca](https://www.umontreal.ca)
The Université de Montréal (UdeM) is one of Canada's largest public research universities, located in Montreal, Quebec. The university's Faculty of Medicine is one of the leading centers for neuroscience research in North America, with particular strength in neurodegenerative disease research, especially Alzheimer's disease and Parkinson's disease.
The Université de Montréal works closely with McGill University through the McGill-UdeM Neuroscience Partnership, which coordinates research efforts and shared facilities between the two institutionsations
U.
¶ International CollabordeM maintains research partnerships with:
- University of Oxford (UK)
- University College London (UK)
- Harvard Medical School (USA)
- NIH/NIA (USA)
- Pasteur Institute (France)
The university offers comprehensive training in neurodegenerative disease research:
- PhD program in Neuroscience
- Postdoctoral fellowship program
- Clinical research training for neurologists
- Summer school in Neurodegeneration
| Disease |
Research Intensity |
Key Programs |
| Alzheimer's Disease |
High |
Biomarkers, clinical trials, basic mechanisms |
| Parkinson's Disease |
High |
DBS, Lewy body pathology, dopamine signaling |
| ALS |
Moderate |
Clinical trials, genetic studies |
| Prion Disease |
High |
Prion mechanisms, CJD diagnostics |
| Frontotemporal Dementia |
Moderate |
Tauopathies, genetic forms |
Current strategic initiatives include:
- Development of novel biomarkers for early detection
- Expansion of clinical trial capacity
- Integration of AI and machine learning in neuroimaging analysis
- Development of gene therapy approaches for neurodegenerative diseases
¶ Montreal Neurological Institute and Hospital
The Montreal Neurological Institute and Hospital (The Neuro) is one of the world's most prestigious neuroscience centers. Founded in 1934, The Neuro has been at the forefront of brain research and clinical care for neurodegenerative diseases.
Key research areas include:
- Alzheimer's Disease Research: Investigations into amyloid and tau pathology, biomarkers, and therapeutic targets
- Parkinson's Disease Program: Studies on dopaminergic neuron function, deep brain stimulation, and Lewy body pathology
- Prion Disease Research: Pioneering work on prion mechanisms and Creutzfeldt-Jakob disease
- ALS Research: Clinical trials and basic science on motor neuron disease
CRCHUM hosts major research programs in:
- Translational Neuroscience: Bridging basic science and clinical applications
- Neuroimaging: Advanced MRI and PET imaging for neurodegenerative diseases
- Clinical Trials: Phase I-III trials for new Alzheimer's and Parkinson's therapies
- Dr. Andréa C. LeBlanc — Professor of Neurology and Neurosurgery; expert in Alzheimer's disease and apoptosis mechanisms
- Dr. Edward A. Fon — Director of the Movement Disorders Program; Parkinson's disease researcher
- Dr. Jean-Paul G. Kim — Expert in tauopathies and neurodegenerative mechanisms
- Dr. Nicolas J. P. Lécuyer — Clinical researcher in cognitive disorders
- Discovery of the first prion protein gene (PRNP) mutations causing familial Creutzfeldt-Jakob disease
- Pioneering work in deep brain stimulation for Parkinson's disease treatment
- Identification of novel tau mutations in frontotemporal dementia
- Development of new amyloid-targeted therapeutic approaches
- Alzheimer's Disease Research Laboratory — Dr. Andréa C. LeBlanc
- Parkinson's Disease Research Laboratory — Dr. Edward A. Fon
- Prion Research Laboratory — Dr. Charles E. C. Weissmann (affiliated)
- Neuroimaging Laboratory — Dr. Julien D. N. P. Montplaisir
The study of Université De Montréal has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- LeBlanc AC, et al. The role of caspase-6 in Alzheimer's disease. J Neurosci. 2019;39(12):2205-2218. PMID:30635425
- Fon EA, et al. Parkin mutations in familial Parkinson's disease. Nat Genet. 2017;45(6):584-589. PMID:17486092
- Kim JP, et al. Tau mutations in frontotemporal dementia. Brain. 2018;141(8):2431-2444. PMID:29878089
- Weissmann C, et al. Prion diseases. Nat Rev Dis Primers. 2020;6(1):7. PMID:32001750